7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
03 juin 2024 12h57 HE
|
7 Hills Pharma
Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
26 avr. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
22 mai 2023 13h05 HE
|
7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS
11 avr. 2022 10h00 HE
|
Invectys, Inc.
Houston, Texas, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company which is developing a next generation of therapies to meet the needs...
INVECTYS INC. TO PARTICIPATE IN THE 2021 ROTH VIRTUAL HEALTHCARE PRIVATE COMPANY FORUM ON JUNE 28TH, 2021
25 juin 2021 11h30 HE
|
Invectys, Inc.
Houston, Texas, USA, June 25, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
Invectys nominates Rosemary Williams, CPA, as Vice-President for Administration and Controller
01 juin 2021 11h00 HE
|
Invectys, Inc.
Houston, TX, USA, June 01, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the...